Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metastases Directed Therapy for Oligometastatic Breast Cancer
Sponsor: National Cancer Institute, Egypt
Summary
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
Official title: Role of Metastases Directed Radiotherapy in Addition to Standard of Care Systemic Treatment in the Management of Extracranial Oligometastatic Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2023-09-20
Completion Date
2028-09-20
Last Updated
2023-11-22
Healthy Volunteers
No
Interventions
Stereotactic Ablative Radiation Therapy
SABR to all metastatic lesions
Locoregional treatment
mastectomy or BCS for the primary tumor
Standard of Care
Systemic treatment and palliative treatment
Locations (1)
National Cancer Institute
Cairo, Egypt